RocketTickers

FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP

Long
NYSE:ABBV   AbbVie Inc
ABBV: AbbVie
2021-09-28 18:00:00
FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine